A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients

被引:25
作者
Szkandera, Joanna [1 ,2 ]
Pichler, Martin [1 ]
Absenger, Gudrun [1 ,2 ]
Stotz, Michael [1 ]
Weissmueller, Melanie [1 ]
Samonigg, Hellmut [1 ]
Asslaber, Martin [3 ]
Lax, Sigurd [5 ]
Leitner, Gerhard [6 ]
Winder, Thomas [7 ]
Renner, Wilfried [4 ]
Gerger, Armin [1 ,2 ]
机构
[1] Med Univ Graz, Dept Med, Div Clin Oncol, A-8036 Graz, Austria
[2] Med Univ Graz, Div Clin Oncol, Res Unit Genet Epidemiol & Pharmacogenet, A-8036 Graz, Austria
[3] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria
[4] Med Univ Graz, Clin Inst Med & Lab Diagnost, A-8036 Graz, Austria
[5] Gen Hosp Graz West, Dept Pathol, Graz, Austria
[6] Gen Hosp Leoben, Dept Pathol, Leoben, Austria
[7] Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland
关键词
COLORECTAL-CANCER PATIENTS; SINGLE NUCLEOTIDE POLYMORPHISMS; FRIZZLED-RELATED PROTEIN; STEM-CELLS; GENETIC-POLYMORPHISM; TARGETING HEDGEHOG; BREAST-CANCER; TUMOR-MARKER; PATHWAY; ASSOCIATION;
D O I
10.1158/1078-0432.CCR-13-1517
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cumulating evidence indicates that germline variants in the Wnt, Notch, and Hedgehog pathways are involved in colon carcinoma progression and metastasis. We investigated germline polymorphisms in a comprehensive panel of Wnt, Notch, and Hedgehog pathway genes to predict time to recurrence (TTR) and overall survival in patients with stage II and III colon carcinoma. Experimental Design: A total of 742 consecutively collected patients with stage II and III colon carcinoma were included in this retrospective study. Genomic DNA was analyzed for 18 germline polymorphisms in Wnt, Notch, and Hedgehog pathway genes (SFRP, DKK 2 and 3, AXIN2, APC, MYC, TCF7L2, NOTCH2, and GLI1) by TaqMan 5'-exonuclease assays. Results: In univariate analysis, the homozygous mutant variant of GLI1 rs2228226G>C was significantly associated with decreased TTR in a recessive genetic model after adjustment for multiple testing [HR = 2.35; confidence interval (95% CI), 1.48-3.74; P < 0.001] and remained significant in multivariate analysis including clinical stage, lymphovascular-, vascular-, and perineural-invasion (HR 2.43; CI 95%, 1.52-3.87; P < 0.001). In subanalyses, the association was limited to patients with surgery alone (HR = 3.21; CI 95%, 1.59-6.49; P = 0.001), in contrast with patients with adjuvant chemotherapy (HR 0.82; CI 95%, 0.35-1.95; P = 0.657). When the subgroup of patients with " high-risk" GLI1 rs2228226 C/C genotype was analyzed, no benefit of adjuvant 5-fluorouracil-based chemotherapy could be found. Conclusion: This is the first study identifying GLI1 rs2228226G>C as an independent prognostic marker in patients with stage II and III colon carcinoma. Prospective studies are warranted to validate our findings.
引用
收藏
页码:1687 / 1697
页数:11
相关论文
共 67 条
[1]   Standards for reporting prognostic tumor marker studies [J].
Alonzo, TA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9053-9054
[2]   U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma [J].
Axelson, Michael ;
Liu, Ke ;
Jiang, Xiaoping ;
He, Kun ;
Wang, Jian ;
Zhao, Hong ;
Kufrin, Dubravka ;
Palmby, Todd ;
Dong, Zedong ;
Russell, Anne Marie ;
Miksinski, Sarah ;
Keegan, Patricia ;
Pazdur, Richard .
CLINICAL CANCER RESEARCH, 2013, 19 (09) :2289-2293
[3]   A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer [J].
Berlin, Jordan ;
Bendell, Johanna C. ;
Hart, Lowell L. ;
Firdaus, Irfan ;
Gore, Ira ;
Hermann, Robert C. ;
Mulcahy, Mary F. ;
Zalupski, Mark M. ;
Mackey, Howard M. ;
Yauch, Robert L. ;
Graham, Richard A. ;
Bray, Gordon L. ;
Low, Jennifer A. .
CLINICAL CANCER RESEARCH, 2013, 19 (01) :258-267
[4]   Genetic variants in frizzled-related protein (FRZB) and the risk of colorectal neoplasia [J].
Berndt, Sonja I. ;
Huang, Wen-Yi ;
Yeager, Meredith ;
Weissfeld, Joel L. ;
Chanock, Stephen J. ;
Hayes, Richard B. .
CANCER CAUSES & CONTROL, 2009, 20 (04) :487-490
[5]   The cancer stem cell: premises, promises and challenges [J].
Clevers, Hans .
NATURE MEDICINE, 2011, 17 (03) :313-319
[6]   Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics [J].
Coate, Linda ;
Cuffe, Sinead ;
Horgan, Anne ;
Hung, Rayjean J. ;
Christiani, David ;
Liu, Geoffrey .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (26) :4029-4037
[7]  
Cortejoso L, 2012, PHARMACOGENOMICS, V13, P1173, DOI [10.2217/PGS.12.95, 10.2217/pgs.12.95]
[8]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[9]   GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes [J].
Dai, Jingyao ;
Gu, Jian ;
Huang, Maosheng ;
Eng, Cathy ;
Kopetz, E. Scott ;
Ellis, Lee M. ;
Hawk, Ernest ;
Wu, Xifeng .
CARCINOGENESIS, 2012, 33 (07) :1327-1331
[10]   Treatment of Metastatic Colorectal Cancer [J].
Davies, Janine M. ;
Goldberg, Richard M. .
SEMINARS IN ONCOLOGY, 2011, 38 (04) :552-560